CTCA Hospitals

Cancer Treatment Hospitals Across the U.S.

Cancer Treatment Centers of America (CTCA) is a network of cancer hospitals with locations throughout the United States. At each state-of-the-art facility, doctors and other clinicians work together to provide cancer patients with personalized care, leading-edge medical treatments and innovative therapies.

Everything we offer at our hospitals—from diagnostic testing to medical treatments to supportive therapies—is available onsite. This allows care team members to communicate, coordinate and thoroughly integrate treatment. Furthermore, at each hospital we offer an array of amenities and services for patients and caregivers to help make their stay comfortable, convenient and enjoyable.

These include:

  • Transportation coordination
  • Lodging arrangements
  • Complimentary courtesy shuttles
  • Concierge services
  • Activities and classes
  • Low-cost, healthy and organic (when available) meals
  • Special outings to local attractions and events

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap